Geron mit Hammernews!! - Älteste Beiträge zuerst (Seite 7)

[meislo]

In March, Geron shares jumped after the company said its experimental cancer vaccine killed a variety of tumor-cell types in laboratory cultures.

The Wall Street Journal reported that Geron has reported intriguing results from its basic research programs several times over the past few years, often fueling a surge in its stock. On most such occasions, however, the share price has fallen back as investors digested the fact that practical applications remained years away.







Im März sprangen Anteile Geron nach der besagten Firma sein experimenteller Krebsimpfstoff töteten eine Vielzahl der Tumor-Zelle eintippt Laborkulturen. Das Wall Street Journal berichtete, daß Geron über intriguing Resultaten von seinen Grundlagenforschungprogrammen mehrmals während der letzten Jahre berichtet hat und eine Schwankung sein auf Lager häufig getankt. Bei den meisten solchen Gelegenheiten jedoch ist der Anteilpreis zurück gefallen, wie Investoren die Tatsache verdauten, daß praktische Anwendungen Jahre entfernt blieben.

wollen wir hoffen das es diesmal nicht nochmal passiert das die Aktie zurück kommt!! Das glaube ich einfach nicht dafür dsind die Umsätze einfach zu stark angestiegen hier hat sich meines Erachtens ein echter Trendwechsel vollzogen

[siam123]

@all,

vielleicht ganz interessant :

http://iw.thomsonfn.com/iwatch/cgi-bin/iw_ticker?ticker=gern…

Gruß,

siam123

[greenhorn1998]

Hi zusammen!

@ meislo
Ich bin da etwas skeptischer. Die Nachrichtenlage wird nicht weiter so fantastisch bleiben. In ein paar Tagen/Wochen fristet Geron wieder ein Hintergrunddasein. Niedrige Umsätze, wahrscheinlich fallende Kurse. Vielleicht benötigt Geron irgendwann frisches Geld? Wahrscheinlich sogar.
Bis neue, positive Nachrichten kommen, z.B. über erfolgreiche Testergebnisse in klinischen Phasen dauert es ein Weilchen.
Ich gehe ehrlich gesagt davon aus, dass Geron etwas zurückkommt, was ich dann auch für einen ersten Einstieg nutzen werde. Ich gebe dir Recht, dass dieser Abfall nicht so dramatisch ausfallen dürfte. Bestimmt sind einige Großinvestoren eingestiegen, Kurse in den Niederungen, wie wir sie gesehen haben (2 Dollar) wird es wahrscheinlich, hoffentlich nicht geben. Aber einen Rücksetzer bestimmt.

Gruß, greenhorn

[meislo]

@Hallo Greenhorn19988


Für mich ist der seit drei Jahren anhaltende Abwärtstrend unter hohen Umsätzen durchbrochen worden und damit sollte der mitte März begonnene Aufwärtstrend weiter in takt sein
Ob es zu einem Rücksetzer kommt kann man nicht ausschliessen
Ich denke aber die dynamische Entwicklung wird weiter gehen

http://finance.yahoo.com/q?s=GERN&d=c&t=my&l=on&z=b&q=l

gruss meislo

[meislo]

@ Hallo Greenhorn1998

Das habe ich im Yahoo- Board gefunden
Wenn das stimmt kommen nächste Woche News die weiter Kuestreibend sein dürften

Re: GRN163 IND delay
by: jonaei 04/02/03 02:32 am
Msg: 81729 of 81735

dow jones: t.o. says it`s fourth quarter for the ind. but good news on the vaccine should come at the meeting next week.

04-01-03 1112ET DJ Geron Up -2: Co Years Away From Marketing Product>GERN

By Hollister H. Hovey
Of DOW JONES NEWSWIRES

[...]

(MORE) Dow Jones Newswires

04-01-03 1229ET =DJ Geron Up -3: Co To Unveil Cancer Trial Results >GERN


The company does have some "real news" pending in the coming months, CEO Okarma said. The company will announce data from an early-stage trial of a telomerase cancer vaccine being studied in prostate cancer patients at the American Association for Cancer Research 2003 meeting, which runs April 5-9.

The company also expects to file an investigational new drug application with the Food and Drug Administration for a different cancer drug sometime in the fourth quarter, he said.

[meislo]

Ist der Ausverkauf bereits beendet?
Aktuell wieder bei 6,85 Dollar ein plus von 2%
Irgendwie witd mir das unheimlich

gruss meislo

[meislo]

Geron stock rises on promising stem cell research
2003-04-01 14:59:50 EST

NEW YORK, April 1 (Reuters) - Shares of Geron Corp. rose as much as 40 percent on Tuesday after it published research indicating it could produce liver cells from stem cells in a way that could help scientists test drugs for liver toxicity.

Shares of the Menlo Park, California-based company rose $1.11 to $6.40 in midafternoon trading on Nasdaq. Earlier they rose as high as $7.40.

Geron showed in the journal Cell Transplantation how its scientists produce hepatocytes, the basic functional cells of the liver, from human embryonic stem cells. Hepatocytes have multiple characteristics, including the ability to metabolize enzymes.

The scientists found that certain proteins found in liver cells are also expressed by those derived from the stem cells.

The enzymes can be used to test whether a potential drug can be metabolized by the liver or whether it is toxic.

If Geron`s method were successful it could allow scientists to reproduce large numbers of liver cells that would enable drug companies to test their drugs for toxicity much earlier in the development process - potentially cutting down the expense of taking drugs that are toxic through clinical trials.

Last month the company`s shares rose $3 after the company said new researched showed its experimental cancer vaccine could be effective against all types of cancer.

[meislo]

In Sachen Krebs gibt es wohl in Zukunft hoffnungsvolle Ansätze auch wenn Geron nicht alleine davon profitieren dürfte so doch viele Menschen die daran erkranhen


Genetisch veränderte Blutzellen als Krebs-Killer
Manipulierte T-Lymphozyten in Laborversuchen wirksam

Manchester (pte, 2. Apr 2003 07:50) - Mittels Genmanipulation ist es Forschern des Paterson Institute for Cancer Research http://www.paterson.man.ac.uk gelungen, aus gewöhnlichen Blutzellen wirksame "Krebskiller" herzustellen. Weiße Blutkörperchen (T-Lymphozyten) wurden so manipuliert, dass sie Tumore erkennen und zerstören. 2004 sind bereits erste Behandlungsversuche an britischen Patienten geplant.

T-Lymphozyten bilden die zelluläre Immunabwehr. Sie schützen das körpereigene Gewebe und lösen gegen Eindringlinge eine Abwehrreaktion aus. Da Krebszellen allerdings vom Körper selbst gebildet werden, ist es für die Immunzellen schwierig, diese zu erkennen und anzugreifen. Die US-Forscher umgingen dieses Problem, indem sie die T-Lymphozyten von Darmkrebs-Patienten manipulierten. Sie verschmolzen ein für Darmkrebs spezifisches so genanntes "Homing"-Gen mit einem "Killer"-Gen, das den Angriff der weißen Blutkörperchen initiiert. Die auf diesem Weg von zehn Probanden manipulierten T-Zellen zeigten den Angaben zufolge eine beeindruckende Anti-Krebs-Aktivität. Das Hybrid-Gen schien dazu zu führen, dass die T-Zellen die Krebszellen zerstörten.

"Wir haben die Immunzellen mit jener Ausrüstung ausgestattet, die sie für die Zerstörung von Tumorzellen benötigen", erklärt der Forscher Robert Hawkins. Im Labor funktionierte die Technik 100-prozentig. Der wahre Test ist aber der Versuch mit Krebspatienten. (Ende)

[meislo]

Ist nicht von mir das nabe ich im yahoo-board gefunden


I took these notes while listening to Geron`s CEO T. Okarma speak at the Feb. 27, 2003 Bio CEO conference.

It is still available at www.geron.com
Click "News", and then "Conference", "Listen" and then fill in your name.
-------------------------------------

Stem Cells
Neurons for Parkinson’s and spinal cord injury are engrafting in our animal models.
Early results (from cardiomyocytes derived from stem cells) in our heart failure animal models.

7 cell types derived

Spinal cord results to be published in April-May time frame.

Spinal cord injury will be our first clinical application

4 lines have passed preliminary safety studies, and one line, H1, has passed the full compliment of FDA tests enabling us to declare the H1 line fully qualified for human use.

Two programs underway to completely solve the rejection problem. 1. pre-dose a patient with the new cell types to desensitize the patient when the therapeutic cells are transplanted
2. Genetically engineer cells to create immunicologically null starting material.

Hepatocytes to be used for drug discovery will be ready when some enzyme levels have been bumped up a little.

Scalability: 1 master cell bank produces 10 million doses for Parkinson’s disease.

Oncology

GRN163 and GRN719 non-toxic inhibitors of telomerase to treat 14 cancer types

GRN719 is the lipidated version of GRN163... better bio availability, systemic administration (no need for localized injection pumps.

5 of 7 test animals cured of tumor, 4 of 4 controls dead by day 43 (s23)

GRN719 may be the compound going to final approval because of the bio availability and systemic administration.

GRN163 GLP and TOX studies underway which are IND enabling.

Roche completed 300 patient study of bladder cancer detection...
79% if measuring telomerase protein, 84% if measuring telomerase RNA versus PSA which has a positive predictive value of only 21%.

Still need to increase sensitivity to not only follow bladder cancer patients, but to also screen patients coming to the clinic.

GRN163/719 first targets: glioblastoma, hipital cellular carcinoma, then lymphoma or myeloma.

Duke: have now treated 14 patients, no results yet. 13/14 patients show immunicological response, no side-effects, even in the one patient who has had 6 vaccinations.

Animal tests of in vivo oncolytic virus are showing the same positive results as the ex-vivo (Duke) test.

in vivo vaccine is being evaluated by a potential "Large" development partner for a potential exclusive license.

Patents
Several new cancer treatment patents and stem cell "process to derive" and "composition of matter" patents.

Our interference proceedings against Infigen and ACT are going very well and we hope to have some good news later this year on that front as well.

Two years of cash in the bank.

Future:

1.Telomerase Promoter patent which will trigger a milestone payment from GTI

2.Patent on an additional hESC derived cell type

3.GRN163 entering the clinic

4.Publications of animal data demonstrating engraphtment and improved functionality

5.Clinical data on the response of the prostrate cancer patients at Duke

6.Continued growth of our IP portfolio

7.Continued growth in the oncology portfolio by licensed partners

[meislo]

Schon wieder was neues zu Geron

Geron Reports Advances in Its Human Embryonic Stem Cell Programs
Thursday April 3, 7:31 am ET
Presentations Demonstrate Engraftment of Dopaminergic Neurons in a Model of Parkinson`s Disease as Well as Characterization and Long-Term Stability Data


MENLO PARK, Calif.--(BUSINESS WIRE)--April 3, 2003-- Geron Corporation (Nasdaq:GERN - News) reported on multiple advances in its human embryonic stem cell (hESC) programs at the 2003 Keystone Symposium entitled "From Stem Cells to Therapy" held in Steamboat Springs, Colorado. Geron scientists presented data showing engraftment of hESC-derived dopaminergic neurons transplanted into the brains of a rat model of Parkinson`s disease and the production of pure populations of hESC-derived cardiomyocytes. Also, in four separate presentations, Geron scientists described studies that defined the properties and biological stability of hESCs over long-term culture.
ADVERTISEMENT


Neurons for Parkinson`s Disease

Geron scientists demonstrated that hESCs can be differentiated into dopaminergic neurons, the therapeutic cell type for the potential treatment of Parkinson`s disease. Using protocols developed at Geron, hESCs were differentiated first into neural progenitors and then into neurons expressing thyrosine hydroxylase - the rate-limiting enzyme for the production of dopamine. The differentiated cells formed robust, viable dopaminergic neural grafts after transplantation into the brains of an established rat model of Parkinson`s disease.

"These results demonstrate that hESCs can be differentiated into target cells which have been difficult to scalably produce by other means," said Jane S. Lebkowski, Ph.D., Geron`s vice president of regenerative medicine. "The survival of the human dopaminergic neurons in the brains of the rat model of Parkinson`s disease shows that these cells can engraft in the adult brain micro-environment."

Cardiomyocytes for Heart Disease

Geron scientists presented new data showing that cardiomyocytes (heart muscle cells) can be derived from hESCs and enriched by a serum-free culture formulation that prevents the growth of unwanted cell populations. These hESC-derived cardiomyocytes displayed appropriate cardiomyocyte molecular markers and responded normally to cardiac drugs used clinically to treat heart disease. These results are important because they predict integration of the hESC-derived cardiomyocytes into damaged heart tissue when transplanted. Furthermore, the results predict that such newly regenerated heart muscle tissue will respond normally to cardioactive drugs.

hESC Stability

Recent Geron data demonstrate that the unique properties of undifferentiated hESCs are fully retained even after long-term continuous culture. Three different hESC lines were cultured long-term using feeder-free conditions (developed by Geron) and monitored for eight cell surface markers. All eight markers were continually expressed for over 70 culture passages (more than one year in continuous culture). This remarkable cellular stability was also reflected by the constant expression during the culture period of telomerase activity and multiple specific transcription factors known to regulate gene expression. Microarray analysis further demonstrated this stability: only 23 of 2,798 tested genes exhibited more than a three-fold change in expression after hESCs were cultured for 12 to 27 weeks. Approximately 80% of individual hESCs cultures maintained their normal complement of chromosomes, and those that developed karyotypic abnormalities could be identified, discarded and replenished from frozen hESC banks. Most importantly, the hESCs remained pluripotent -- capable of differentiating into cells of all major lineages of the body -- even after nearly one and one half years in continuous culture.

"These data show that hESCs have very stable properties when scalably propagated in feeder-free culture," stated Thomas B. Okarma, Ph.D., M.D., Geron`s president and chief executive officer. "This important and unique feature of hESCs validates our product model for commercialization of hESC-based therapies. The therapeutic cells can be manufactured in large, multi-dose lots, shipped and stored frozen for `off the shelf` use by healthcare providers."

hESC Qualification

Finally, Geron presented data on the qualification and culture of hESCs for human therapeutic use. Qualification of hESCs establishes safety and consistency criteria necessary for use in human testing.

Four hESC lines, originally derived at the University of Wisconsin-Madison, were tested for sterility and various human pathogens including HIV 1 & 2, human T-cell leukemia viruses 1 & 2, human cytomegalovirus, and hepatitis B & C viruses. All four hESC lines showed no evidence of infection with any of these human pathogens. In addition, the H1 cell line was extensively tested for infection by pathogens that could have contaminated the reagents used to derive or culture that particular hESC line. No evidence was found for H1 line infection by viruses of human, porcine, murine, or bovine origin. Other results presented by Geron at the meeting demonstrated that defined and highly purified reagents can be used to culture hESCs, enabling the development of manufacturing specifications for hESC-based products that will meet the high standards required for human therapeutic use.

Geron is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, and research tools for drug discovery. Geron`s product development programs are based upon three patented core technologies: telomerase, human embryonic stem cells and nuclear transfer.

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding future applications of Geron Corporation`s technology constitute forward-looking statements involving risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, need for additional capital, need for regulatory approvals or clearances, and the maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron`s periodic reports, including the annual report on Form 10-K for the year ended on December 31, 2002